Inherited retinal diseases target of potential treatments

Article

Forty potential new treatments for inherited retinal diseases are under development, according to a review by the National Institute for Health Research (NIHR) Horizon Scanning Centre (HSC), working with charitable organization Fight for Sight.

Forty potential new treatments for inherited retinal diseases are under development, according to a review by the National Institute for Health Research (NIHR) Horizon Scanning Centre (HSC), working with charitable organization Fight for Sight.

The promising technologies - identified through consultations and focus groups with patients, families, caregivers and eye health professionals - include nine gene therapy approaches, ten medical devices, five drugs and five regenerative and cell development approaches. Eleven additional technologies are at a very early stage of development. Most of the technologies identified are in clinical trials or are expected to be soon.

"With further support and funding, these therapies and technologies could have a major impact on people's lives," says Michele Acton, chief executive of Fight for Sight.

For more information on the review visit the NIHR HSC website here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.